|
|
Pharmacy Information 2024
介绍一种不影响D2受体的新型抗精神病候选药物：SEP-363856
|
Abstract:
本文介绍一种在2020年被美国FDA批准用于临床精神分裂症的新型抗精神分裂症药物：SEP-363856。从该药物的药代动力学、受体作用机制、临床运用情况以及安全性和不良反应等方面作了总结。结论：SEP-363856治疗精神分裂症的阴、阳性症状均有效，且安全性、耐受性好，需要进一步扩大样本研究。
The article introduces a novel antipsychotic drug, SEP-363856, approved by US FDA for clinical use in schizophrenia in 2020. A summary was made on the pharmacokinetics, receptor mechanism of action, clinical application, safety, and adverse reactions of the drug. Conclusion: SEP-363856 is effective in treating both negative and positive symptoms of schizophrenia and is safe and well tolerated. Further expansion of sample research is needed.
| [1] | Koblan, K.S., Kent, J., Hopkins, S.C., Krystal, J.H., Cheng, H., Goldman, R., et al. (2020) A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. New England Journal of Medicine, 382, 1497-1506. https://doi.org/10.1056/nejmoa1911772 |
| [2] | (2020) Sunovion and Psychogenics Announce That SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia. https://www.businesswire.com |
| [3] | Dedic, N., Jones, P.G., Hopkins, S.C., Lew, R., Shao, L., Campbell, J.E., et al. (2019) SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics, 371, 1-14. https://doi.org/10.1124/jpet.119.260281 |
| [4] | Liu, H., Zheng, Y., Wang, Y., Wang, Y., He, X., Xu, P., et al. (2023) Recognition of Methamphetamine and Other Amines by Trace Amine Receptor TAAR1. Nature, 624, 663-671. https://doi.org/10.1038/s41586-023-06775-1 |
| [5] | Christian, S.L. and Berry, M.D. (2018) Trace Amine-Associated Receptors as Novel Therapeutic Targets for Immunomodulatory Disorders. Frontiers in Pharmacology, 9, Article 680. https://doi.org/10.3389/fphar.2018.00680 |
| [6] | Koblan, K., Hopkins, S., Kent, J., et al. (2019) Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial. European Neuropsychopharmacology, 29, S85-S86. http://doi.org/10.1016/j.euroneuro.2019.09.154 |
| [7] | Dedic, N., Jones, P.G., Hopkins, S.C., Lew, R., Shao, L., Campbell, J.E., et al. (2019) SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics, 371, 1-14. https://doi.org/10.1124/jpet.119.260281 |
| [8] | Miyamoto, S., Duncan, G.E., Marx, C.E. and Lieberman, J.A. (2004) Treatments for Schizophrenia: A Critical Review of Pharmacology and Mechanisms of Action of Antipsychotic Drugs. Molecular Psychiatry, 10, 79-104. https://doi.org/10.1038/sj.mp.4001556 |
| [9] | Karam, C.S., Ballon, J.S., Bivens, N.M., Freyberg, Z., Girgis, R.R., Lizardi-Ortiz, J.E., et al. (2010) Signaling Pathways in Schizophrenia: Emerging Targets and Therapeutic Strategies. Trends in Pharmacological Sciences, 31, 381-390. https://doi.org/10.1016/j.tips.2010.05.004 |
| [10] | Girgis, R.R., Zoghbi, A.W., Javitt, D.C. and Lieberman, J.A. (2019) The Past and Future of Novel, Non-Dopamine-2 Receptor Therapeutics for Schizophrenia: A Critical and Comprehensive Review. Journal of Psychiatric Research, 108, 57-83. https://doi.org/10.1016/j.jpsychires.2018.07.006 |
| [11] | Milanovic, S., Origala, A., Dworak, H., Hopkins, S. and Koblan, K. (2020) M208. Measures of Cognition and Social Functioning in Schizophrenia Patients Receiving SEP-363856. Schizophrenia Bulletin, 46, S215-S216. https://doi.org/10.1093/schbul/sbaa030.520 |
| [12] | Begni, V., Sanson, A., Grayson, B., Neill, J. and Riva, M.A. (2019) T109. Modulatory Activity of the Novel Drug Sep-363856 on Brain Function: Potential Application for the Treatment of Schizophrenia. Schizophrenia Bulletin, 45, S246-S246. https://doi.org/10.1093/schbul/sbz019.389 |
| [13] | Koblan, K., Hopkins, S., Justine, K., Hailong, C., Goldman, R. and Loebel, A. (2019) O12.5. Efficacy and Safety of Sep-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial. Schizophrenia Bulletin, 45, S199. https://doi.org/10.1093/schbul/sbz021.269 |
